997 results on '"Valent, Peter"'
Search Results
2. CD8+ T-cell Differentiation and Dysfunction Inform Treatment Response in Acute Myeloid Leukemia
3. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes
4. Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry
5. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
6. 15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives
7. Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee
8. Reversible Elevation of Tryptase Over the Individual's Baseline: Why is It the Best Biomarker for Severe Systemic Mast Cell Activation and MCAS?
9. Coronavirus Receptor Expression Profiles in Human Mast Cells, Basophils, and Eosinophils
10. Clonal medicine targeting DNA damage response eradicates leukemia
11. Characterization of Patients with Clonal Mast Cells in the Bone Marrow with Clinical Significance Not Otherwise Specified
12. TNF alpha promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis
13. Hyper-resolution flood hazard mapping at the national scale
14. Effects of the application of biochar on the soil erosion of plots of sloping agricultural and with silt loam soil
15. The testing of a multivariate probabilistic framework for reservoir safety evaluation and flood risks assessment in Slovakia: A study on the Parná and Belá Rivers
16. Affective temperament, fatigue, and pain in cancer patients
17. KIT Mutations and Other Genetic Defects in Mastocytosis
18. Megafloods in Europe can be anticipated from observations in hydrologically similar catchments
19. Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma
20. Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma
21. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
22. The impact of COVID-19 and socioeconomic status on psychological distress in cancer patients
23. ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia
24. CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS
25. History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis
26. Mastocytosis: Overview of Diagnosis and Classification
27. PB2476: TARGETING OF BRD4 TO COUNTERACT CYTOKINE-INDUCED EXPRESSION OF PD-L1 AND PD-L2 ON VASCULAR, OSTEOBLASTIC AND STROMAL NICHE CELLS
28. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
29. Vienna Cancer Stem Cell Club (VCSCC): 20 year jubilee and future perspectives
30. Risk as a pattern over time: Delineation of time‐dependent risk factors in biological, psychological, and social variables in cancer patients
31. Increased TIM-3 and GAL-9 serum levels in patients with advanced systemic mastocytosis
32. World Health Organization Classification and Diagnosis of Mastocytosis
33. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
34. Mastocytosis
35. Genetic Variants Leading to Urticaria and Angioedema and Associated Biomarkers
36. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry
37. Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
38. Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis
39. Supplementary Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
40. Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
41. Supplementary Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
42. Abstract 6168: Implementation and adoption of a web tool to support precision diagnostic and treatment decisions for patient with myelodysplastic syndromes
43. Supplementary Figure from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
44. Supplementary Figure from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
45. Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
46. Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
47. Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
48. Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
49. Supplemental Table S3 from Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future
50. Supplementary Table 6 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.